Captopril potentiates the anticonvulsant activity of carbamazepine and lamotrigine in the mouse maximal electroshock seizure model

Journal of Neural Transmission

Volumn 117, Issue 10, 2010, Pages 1161-1166

  Łukawski, Krzysztof ^a   Jakubus, Tomasz ^a   Raszewski, Grzegorz ^a   Czuczwar, Stanisław J ^a,b  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antiepileptic drugs; Captopril; Maximal electroshock; Pharmacodynamic interactions

Indexed keywords

CAPTOPRIL; CARBAMAZEPINE; LAMITRIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN; CHIMNEY; CONTROLLED STUDY; CONVULSION; DRUG EFFECT; ELECTRIC SHOCK; ELECTROSTIMULATION; EPILEPSY; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; SEIZURE; TASK PERFORMANCE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTICONVULSANTS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; DISEASE MODELS, ANIMAL; ELECTROSHOCK; EPILEPSY, TONIC-CLONIC; MALE; MICE;

EID: 78651262546     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0455-y     Document Type: Article

References (33)

1. JR Boissier J Tardy JC Diverres 1960 Une nouvelle methode simple pour explorer l'action 'tranquilisante': le test de la cheminee Med Exp (Basel) 3 81 84 1:CAS:528:DyaF3MXlsFOktg%3D%3D 10.1159/000134913
2. KK Borowicz M Swiader W Zgrajka C Sawulski WA Turski SJ Czuczwar 2002 Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice J Physiol Pharmacol 53 859 869 1:CAS:528: DC%2BD3sXltFCruw%3D%3D 12510869
3. JJ Braszko W Karwowska-Polecka D Halicka PR Gard 2003 Captopril and enalapril improve cognition and depressed mood in hypertensive patients J Basic Clin Physiol Pharmacol 14 323 343 1:CAS:528:DC%2BD2cXlt1eqsLc%3D 15198305
4. DW Cushman FL Wang WC Fung GJ Grover CM Harvey RJ Scalese SL Mitch JM DeForrest 1989 Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE) Br J Clin Pharmacol 28 Suppl 2 115S 130S 1:CAS:528:DyaK3cXkvVCluw%3D%3D 2557876
5. SJ Czuczwar PN Patsalos 2001 The new generation of GABA enhancers CNS Drugs 15 339 350 1:CAS:528:DC%2BD3MXkt1Ols7Y%3D 10.2165/00023210-200115050-00001 11475940
6. Czuczwar SJ, Włodarczyk D, Ga̧sior M, Kleinrok Z (1991) Is there a glycinergic component in the mechanism of action of common antiepileptic drugs? In: Klee MR, Lux HD, Speckmann EJ (eds) Physiology, pharmacology and development of epileptogenic phenomena. Springer, Berlin, pp 255-257
7. M de Gasparo KJ Catt T Inagami JW Wright T Unger 2000 International Union of Pharmacology. XXIII. The angiotensin II receptors Pharmacol Rev 52 415 472 10977869
8. JS Duncan JW Sander SM Sisodiya MC Walker 2006 Adult epilepsy Lancet 367 1087 1100 10.1016/S0140-6736(06)68477-8 16581409
9. MD Evered MM Robinson MA Richardson 1980 Captopril given intracerebroventricularly, subcutaneously or by gavage inhibits angiotensin-converting enzyme activity in the rat brain Eur J Pharmacol 68 443 449 1:CAS:528:DyaL3MXns1ygtQ%3D%3D 10.1016/0014-2999(80)90419-7 6258934 (Pubitemid 11197456)
10. A Gaitatzis K Carroll A Majeed WJ Sander 2004 The epidemiology of the comorbidity of epilepsy in the general population Epilepsia 45 1613 1622 10.1111/j.0013-9580.2004.17504.x 15571520 (Pubitemid 39648287)
11. PR Gard 2002 The role of angiotensin II in cognition and behaviour Eur J Pharmacol 438 1 14 1:CAS:528:DC%2BD38XitFWkt70%3D 10.1016/S0014-2999(02)01283-9 11906704 (Pubitemid 34242913)
12. CI Johnston 1990 Biochemistry and pharmacology of the renin-angiotensin system Drugs 39 Suppl 1 21 31 1:CAS:528:DyaK3cXhsFWqs78%3D 10.2165/00003495- 199000391-00005 2407490
13. H Kubová P Mares 1994 Effects of MK-801 (dizocilpine) and ketamine on strychnine-induced convulsions in rats: comparison with benzodiazepines and standard anticonvulsants Physiol Res 43 313 320 7711010
14. P Kwan GJ Sills MJ Brodie 2001 The mechanisms of action of commonly used antiepileptic drugs Pharmacol Ther 90 21 34 1:CAS:528:DC%2BD3MXltVCqt7k%3D 10.1016/S0163-7258(01)00122-X 11448723 (Pubitemid 32622838)
15. JH Laragh DB Case SA Atlas JE Sealey 1980 Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor Hypertension 2 586 593 1:STN:280:DyaL3c3kvVarsw%3D%3D 6156900
16. JT Litchfield F Wilcoxon 1949 A simplified method of evaluating dose-effect experiments J Pharmacol Exp Ther 96 99 113 1:CAS:528: DyaH1MXjvFWmsA%3D%3D 18152921
17. W Löscher 1998 New visions in the pharmacology of anticonvulsion Eur J Pharmacol 342 1 13 10.1016/S0014-2999(97)01514-8 9544786 (Pubitemid 28131339)
18. W Löscher 2002 Basic pharmacology of valproate CNS Drugs 10 669 694 10.2165/00023210-200216100-00003
19. W Löscher CP Fassbender B Nolting 1991 The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models Epilepsy Res 8 79 94 10.1016/0920-1211(91)90075-Q 2065646
20. JJ Luszczki SJ Czuczwar 2005 How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol Rep 57 782 786 16382197
21. FJ Minano JS Serrano M Sancibrian MI Serrano 1987 Effect of peptidyl-dipeptidase inhibitors in experimental convulsions in mice Fundam Clin Pharmacol 1 77 83 1:CAS:528:DyaL1cXksVygsLY%3D 10.1111/j.1472-8206.1987.tb00547. x 2824310
22. P Mojaverian BN Swanson RK Ferguson 1984 Enalapril, a new nonsulfhydryl angiotensin converting enzyme inhibitor, does not potentiate morphine analgesia Eur J Pharmacol 98 303 306 1:CAS:528:DyaL2cXhsFSlt7s%3D 10.1016/0014-2999(84) 90607-1 6325220 (Pubitemid 14156894)
23. SK Ng WA Hauser JC Brust M Susser 1993 Hypertension and the risk of new-onset unprovoked seizures Neurology 43 425 428 1:STN:280: DyaK3s7ntlehtw%3D%3D 8437714
24. SL Peterson JP Trzeciakowski GD Frye HR Adams 1990 Potentiation by glycine of anticonvulsant drugs in maximal electroshock seizures in rats Neuropharmacology 29 399 409 1:CAS:528:DyaK3cXktVSntr4%3D 10.1016/0028-3908(90) 90100-6 2342638 (Pubitemid 20113901)
25. S Rajendra JW Lynch PR Schofield 1997 The glycine receptor Pharmacol Ther 73 121 146 1:CAS:528:DyaK2sXisFKiu7k%3D 10.1016/S0163-7258(96)00163-5 9131721 (Pubitemid 27191614)
26. B Rubin MJ Antonaccio ZP Horovitz 1978 Captopril (SQ 14, 225) (D-3-mercapto-2-methylpropranoyl-l-proline): a novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent Prog Cardiovasc Dis 21 183 194 1:CAS:528:DyaE1MXotVCnsQ%3D%3D 10.1016/0033-0620(78)90024-5 214818 (Pubitemid 9068239)
27. S Sangiah 1985 Effects of glycine and other inhibitory amino acid neurotransmitters on threshold in mice Vet Hum Toxicol 27 97 99 1:CAS:528:DyaL2MXhvF2jtb0%3D 3922104
28. J Tchekalarova V Georgiev 2005 Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility? Life Sci 76 955 970 1:CAS:528:DC%2BD2cXhtVyqsb%2FE 10.1016/j.lfs.2004.10.012 15607326 (Pubitemid 39643397)
29. GS Thind 1990 Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics Cardiovasc Drugs Ther 4 199 206 1:STN:280:DyaK3M7jslantg%3D%3D 10.1007/BF01857634 2285612
30. P Venault G Chapouthier L Prado de Carvalho J Simiand M Morre RH Dodd J Rossier 1986 Benzodiazepine impairs and β-carboline enhances performance in learning and memory tasks Nature 321 864 866 1:CAS:528:DyaL28Xkslamtrg%3D 10.1038/321864a0 3724846
31. JW Wright JW Harding 1997 Important roles for angiotensin III and IV in the brain renin-angiotensin system Brain Res Rev 25 96 124 1:CAS:528: DyaK2sXlvVKntbk%3D 10.1016/S0165-0173(97)00019-2 9370053 (Pubitemid 27459723)
32. JW Wright BJ Yamamoto JW Harding 2008 Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets Prog Neurobiol 84 157 181 1:CAS:528:DC%2BD1cXhsVKgt7c%3D 10.1016/j.pneurobio.2007.10. 009 18160199
33. H Yamashita K Ohno Y Amada H Hattori Y Ozawa-Funatsu T Toya H Inami J Shishikura S Sakamoto M Okada T Yamaguchi 2004 Effects of 2-[N-(4-chlorophenyl)- N-methylamino]-4H-pyrido[3.2-e]-1, 3-thiazin-4-one (YM928), an orally active alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats J Pharmacol Exp Ther 308 127 133 1:CAS:528:DC%2BD2cXmsFehsQ%3D%3D 10.1124/jpet.103.058495 14569061 (Pubitemid 38090710)